Tresiba for Prediabetes: What the Evidence Actually Says

What Is Prediabetes and Why Does Drug Choice Matter?

Prediabetes is defined by a fasting plasma glucose of 100-125 mg/dL, a 2-hour glucose of 140-199 mg/dL on an oral glucose tolerance test, or an A1c of 5.7%-6.4% [1]. Without intervention, roughly 37% of U.S. adults meeting these criteria progress to type 2 diabetes within five years [2]. The treatment decision tree matters because the wrong intervention can produce iatrogenic hypoglycemia without meaningfully changing long-term outcomes.

The Diabetes Prevention Program (DPP, N=3,234) remains the benchmark. Intensive lifestyle modification reduced diabetes incidence by 58% at three years versus placebo, while metformin reduced it by 31% [3]. Those numbers set a high bar for any drug that lacks specific prediabetes data to clear. Insulin degludec does not yet clear that bar in this population.

Prediabetes represents a state of relative insulin resistance and impaired first-phase insulin secretion, not absolute insulin deficiency [4]. Injecting exogenous basal insulin addresses only one part of that physiology and adds hypoglycemia risk without proven superiority to lifestyle or oral agents for most patients. That clinical reality shapes every recommendation that follows.

Is Tresiba FDA-Approved for Prediabetes?

Insulin degludec (Tresiba, Novo Nordisk) received FDA approval in September 2015 for glycemic control in adults and pediatric patients aged one year and older with type 1 or type 2 diabetes [5]. The approved label contains no indication for prediabetes, impaired fasting glucose, or impaired glucose tolerance.

The FDA's position reflects the absence of adequate and well-controlled trials in the prediabetes population [5]. Because prediabetes is a risk state rather than a disease requiring insulin replacement, the agency has not been petitioned to add that indication, and no NDA supplement for this use is currently listed in the FDA's drug approval database.

Prescribing degludec for prediabetes is therefore an off-label use. Off-label prescribing is legal for licensed physicians, but it shifts the burden of informed consent, documentation, and outcome monitoring entirely onto the prescribing clinician. The ADA's 2024 Standards of Medical Care in Diabetes explicitly list lifestyle intervention and metformin as the only pharmacotherapies with sufficient evidence to recommend for diabetes prevention [6].

What Does the Clinical Evidence Show for Prediabetes?

No published randomized controlled trial has evaluated insulin degludec specifically in a prediabetes population. This is the central evidentiary gap. The following trials provide adjacent data that clinicians sometimes extrapolate from, but none were designed to answer the prediabetes question.

DEVOTE (NEJM 2017, N=7,637) compared degludec U-100 to glargine U-100 in patients with type 2 diabetes and high cardiovascular risk over a median 2-year follow-up [7]. Degludec was non-inferior to glargine on the primary three-point MACE endpoint (HR 0.91 to 95% CI 0.78-1.06) and produced 27% fewer confirmed nocturnal hypoglycemic episodes (rate ratio 0.73 to 95% CI 0.60-0.89, P<0.001) [7]. These findings matter for safety extrapolation, not for efficacy in prediabetes.

ORIGIN (NEJM 2012, N=12,537) tested glargine U-100 (a related basal analog, not degludec) in people with dysglycemia including prediabetes and early type 2 diabetes [8]. After six years, glargine did not reduce cardiovascular events compared to standard care. A1c was modestly lower in the insulin group, but the absolute rate of type 2 diabetes diagnosis was not significantly reduced [8]. If the structurally similar glargine failed to show meaningful benefit in this adjacent population over six years, the evidentiary case for degludec in prediabetes is weak.

BEGIN trials (2012-2013): The BEGIN program enrolled patients with type 2 diabetes, not prediabetes. BEGIN ONCE LONG (N=1,030) showed degludec produced similar A1c reductions to glargine with fewer nocturnal hypoglycemia events [9]. Again, useful for safety benchmarking, not for prediabetes efficacy.

The practical takeaway: no trial data support routine use of insulin degludec in prediabetes, and the closest analog trial (ORIGIN with glargine) produced a neutral result. Any prescriber using degludec for this indication should document that the patient has failed lifestyle intervention of at least six months duration, failed or is contraindicated to metformin, and has a fasting glucose consistently at the upper end of the prediabetes range (above 110 mg/dL) with objective evidence of significant insulin resistance such as a HOMA-IR above 2.5 [10].

How Does Tresiba Differ from Other Basal Insulins?

Degludec's pharmacokinetic profile distinguishes it from older basal insulins in ways that are clinically relevant even when used off-label. The drug forms multi-hexameric chains after subcutaneous injection, creating a subcutaneous depot that releases monomers slowly into the circulation [11]. The result is a half-life of approximately 25 hours and a duration of action exceeding 42 hours, compared to roughly 20-24 hours for glargine U-300 and 18-26 hours for glargine U-100 [11].

This flat, peakless profile is associated with lower within-subject variability in glucose-lowering effect. A crossover pharmacodynamic study (N=54) found the coefficient of variation for the glucose infusion rate was 20% with degludec versus 82% with NPH insulin [12]. Lower variability translates to more predictable glucose lowering and a reduced chance of unintended nocturnal hypoglycemia.

For a prediabetes patient who already has adequate endogenous insulin secretion most of the time, that reduced variability is the primary safety argument that off-label proponents cite. A drug with a flatter action curve is less likely to overshoot and cause hypoglycemia compared to NPH or premixed insulins. That argument has pharmacologic logic, though it has not been tested in a prediabetes-specific trial.

Degludec is available in two concentrations: U-100 (100 units/mL in a 3 mL FlexTouch pen) and U-200 (200 units/mL in a 3 mL FlexTouch pen) [5]. For off-label prediabetes use, only U-100 is appropriate given the low doses involved. The U-200 pen delivers the same number of units in half the volume and carries significant overdose risk if a patient or clinician confuses concentrations.

Tresiba Dosing for Prediabetes: Off-Label Considerations

No evidence-based dosing protocol for insulin degludec in prediabetes exists in published guidelines. The following represents clinical extrapolation from type 2 diabetes insulin-naive initiation protocols, adjusted for the milder degree of insulin deficiency in prediabetes [6, 13].

A conservative starting dose is 10 units subcutaneously once daily, administered at the same time each day. Because degludec's half-life exceeds 25 hours, dose timing can shift by up to 8 hours without meaningful pharmacokinetic disruption per the FDA label [5]. This flexibility is useful for patients with irregular schedules, though consistency is still preferred.

Titration should proceed slowly. A structured titration protocol from the BEGIN trials used 2-unit increments every 3 days, targeting a fasting self-monitored glucose below 90 mg/dL [9]. For prediabetes, a more conservative fasting target of 80-100 mg/dL is appropriate to avoid the overcorrection that produces hypoglycemia. If fasting glucose consistently reads below 80 mg/dL, the dose should be reduced by 2 units immediately [6].

Patients must own and use a calibrated glucometer before degludec is prescribed. Fasting glucose should be checked every morning. Any reading below 70 mg/dL (3.9 mmol/L) constitutes a hypoglycemic event per ADA criteria and warrants a same-day call to the prescribing clinician [6]. Readings below 54 mg/dL (3.0 mmol/L) are classified as clinically significant hypoglycemia and require immediate dose reduction and consideration of drug discontinuation [6].

What Side Effects Matter for Prediabetes Patients on Tresiba?

The dominant safety concern is hypoglycemia. Prediabetes patients retain significant endogenous insulin secretion, so exogenous basal insulin stacks on top of an already-functioning system. The risk is not theoretical. In the DEVOTE trial, even patients with established type 2 diabetes experienced severe hypoglycemia at a rate of 0.73 events per 100 patient-years with degludec [7]. For patients with only mildly impaired glucose regulation, the absolute risk of any hypoglycemia is likely higher if doses are not carefully calibrated.

Weight gain is the second concern. Basal insulin therapy consistently produces modest weight gain, averaging 1.5-3.0 kg in the first year of type 2 diabetes trials [9]. For a prediabetes patient in whom obesity is often already a contributing factor, additional weight gain can worsen insulin resistance and partly undermine the purpose of treatment [4].

Injection site reactions occur in a minority of patients. Lipohypertrophy (fatty lumps from repeated injections at the same site) reduces insulin absorption and can cause unpredictable glucose swings [14]. Rotating injection sites within the same anatomical region (abdomen, thigh, or upper arm) reduces this risk. The FDA label recommends site rotation and avoiding injecting into areas with lipohypertrophy [5].

Allergic reactions to degludec itself are rare but reported. Systemic reactions including rash, dyspnea, and hypotension require immediate discontinuation and emergency evaluation [5]. Patients should be counseled on signs of allergic response before leaving the clinic with their first prescription.

Hypokalemia can occur with any insulin due to potassium shift into cells. Routine electrolyte monitoring is not standard for low-dose basal insulin, but patients on potassium-depleting diuretics or with known baseline hypokalemia should have potassium checked within the first month of therapy [5].

Lifestyle and Evidence-Based Alternatives to Tresiba for Prediabetes

Before any pharmacotherapy, structured lifestyle intervention should be tried and documented. The DPP showed that 150 minutes per week of moderate-intensity physical activity combined with a 5%-7% weight loss target produced a 58% relative risk reduction in progression to diabetes [3]. This is the highest-quality evidence available for prediabetes management.

Metformin is the only drug with an ADA recommendation (Grade B evidence) for pharmacotherapy in prediabetes, specifically for patients with BMI above 35 kg/m2, age below 60 years, or a history of gestational diabetes [6]. The standard dose range is 850-1 to 700 mg per day in divided doses, titrated slowly to reduce gastrointestinal side effects. Metformin's absolute risk reduction for diabetes progression in DPP was 31%, achieved at minimal cost and with a well-characterized safety profile extending over 15 years of follow-up in the DPP Outcomes Study [3, 15].

GLP-1 receptor agonists such as semaglutide have accumulated substantial weight-loss and glycemic data in populations that overlap with prediabetes. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [16]. Weight loss of that magnitude frequently normalizes fasting glucose in prediabetes patients, though semaglutide carries no FDA indication for prediabetes prevention either.

Tirzepatide (Mounjaro/Zepbound) similarly produced mean weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial (N=2,539) [17]. These agents may represent a more physiologically appropriate intervention for insulin-resistant prediabetes patients than basal insulin alone, and their evidence base in adjacent populations is considerably stronger.

Does Insurance Cover Tresiba for Prediabetes?

Coverage for insulin degludec when prescribed for prediabetes is almost universally denied. Major commercial payers and CMS classify prediabetes as a preventive indication, and insulin products are approved drugs for treatment of diagnosed diabetes. Without an on-label indication, prior authorization requests for degludec submitted with a prediabetes diagnosis code (ICD-10: R73.09 for prediabetes or E11.65 for type 2 diabetes with hyperglycemia) are routinely rejected [18].

The cash price for Tresiba FlexTouch (5 pens, 3 mL each, 100 units/mL) at retail pharmacy is approximately $550-$650 per month without insurance. Novo Nordisk's patient assistance program (My$99Insulin) caps out-of-pocket cost at $99 per month for eligible commercially insured patients, but program eligibility requires a type 1 or type 2 diabetes diagnosis on file [19]. Patients prescribed degludec for prediabetes would not qualify for this cap.

Generic insulin options (biosimilar glargine products such as Semglee, which costs roughly $100-$150 per month) represent a substantially lower-cost alternative if a prescriber determines basal insulin is medically necessary and the patient cannot afford branded degludec [20]. From a pharmacoeconomic standpoint, this cost differential is a strong argument against degludec specifically for off-label prediabetes use when a biosimilar basal analog at a fraction of the price would deliver comparable glucose-lowering.

Monitoring and Follow-Up for Patients Who Receive Tresiba Off-Label

Patients receiving degludec off-label for prediabetes require more intensive follow-up than those on standard lifestyle modification. A reasonable monitoring schedule includes a fasting glucose log reviewed at each visit, an A1c check at 3 months and 6 months after initiation, a weight check at each visit, and a hypoglycemia event log.

The treatment goal should be normalization of fasting glucose to below 100 mg/dL and A1c to below 5.7%, which would represent reversal of prediabetes by diagnostic criteria [1]. If those targets are not met at 6 months, the off-label trial should be considered a failure and the regimen re-evaluated. If the patient develops confirmed hypoglycemia below 70 mg/dL more than twice in a month, the dose should be reduced by at least 10% or discontinued.

Continuous glucose monitoring (CGM) devices such as the Dexterity or the FreeStyle Libre 3 are not routinely indicated for prediabetes but may be considered for patients on basal insulin who have difficulty recognizing hypoglycemia symptoms [21]. CGM data also provides a 14-day glucose pattern that is more informative for dose titration than intermittent fingerstick logs.

The prescribing clinician should document the medical rationale for insulin use in prediabetes, the patient's prior treatment history, the informed consent discussion including the off-label nature of the prescription, and a defined discontinuation plan if goals are not met. This documentation protects both the patient and the physician should a payer audit or adverse event occur.

When Should a Prediabetes Patient See an Endocrinologist?

A referral to a board-certified endocrinologist is appropriate whenever a primary care clinician is considering insulin for prediabetes. The American Association of Clinical Endocrinology (AACE) recommends specialist involvement when pharmacotherapy beyond metformin is being considered for glucose management in pre-diabetic or early diabetic states [22]. Referral is also warranted if a patient has a fasting glucose consistently above 120 mg/dL (approaching the type 2 diabetes diagnostic threshold of 126 mg/dL), a rapidly worsening A1c trajectory, or comorbidities such as chronic kidney disease that complicate drug selection.

An endocrinologist can order a fasting C-peptide and insulin level to quantify endogenous insulin reserve, which directly informs whether exogenous basal insulin is physiologically logical. A patient with a fasting C-peptide above 3 ng/mL already has substantial insulin secretory capacity, and adding exogenous insulin without addressing insulin resistance pharmacologically or behaviorally treats a surrogate marker rather than the underlying mechanism [23].